Similarly, the model predicts greater sensitivity (lower IC50) to isocitrate dehydrogenase (IDH) inhibitors in patients with mutant IDH (mIDH) gliomas compared to wild-type IDH (wtIDH) cases (Figure 1(BII)). Here, IDH3A is linked to central nervous system cancer.